Meanwhile, lumbrokinase enhances the therapeutic efficacy of chemotherapeutics and partly reverses the chemoresistance of NSCLC cells via the inactivation of NF-κB signaling, reducing the translocation of p50/p65 from the cytoplasm to the nucleus and their binding to the COX-2 promoter, thereby inhibiting COX-2 expression. The gene discussed is NFKB1; the disease is non-small cell lung carcinoma.